Abstract
Mitochondria are recognized as the producers of the majority of energy cells need for their normal activity. After the initial comprehension of how mitochondrial oxidative phosphorylation produces energy, mitochondrial research was not a priority for most cell biologists until novel mitochondrial functions were identified. In fact, it is now known that mitochondria are not only involved in cell calcium homeostasis, intermediate metabolism and free radical generation but are also a crucial crossroad for several cell death pathways. The notion that several clinically used drugs and other xenobiotics induce organ degeneration through damaging mitochondrial bioenergetics led to the use of the organelle as an effective and reliable bio-sensor to predict drug safety. Classic methods used to test the toxicity of a wide range of compounds on isolated mitochondrial fractions were later replaced by novel high-throughput methods to investigate the safety of a very large number of new molecules. Without surprise, the assessment of “mitochondrial safety” for new discovered molecules is of clear interest for pharmaceutical companies which can now select compounds lacking mitochondrial toxicity to undergo further trials, thus avoiding the possibility of later human toxicity due to mitochondrial liabilities.
Keywords: Mitochondria, drug safety, toxicity, high-throughput methods, biosensor
Current Drug Safety
Title: Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Volume: 4 Issue: 1
Author(s): Claudia V. Pereira, Ana C. Moreira, Susana P. Pereira, Nuno G. Machado, Filipa S. Carvalho, Vilma A. Sardao and Paulo J. Oliveira
Affiliation:
Keywords: Mitochondria, drug safety, toxicity, high-throughput methods, biosensor
Abstract: Mitochondria are recognized as the producers of the majority of energy cells need for their normal activity. After the initial comprehension of how mitochondrial oxidative phosphorylation produces energy, mitochondrial research was not a priority for most cell biologists until novel mitochondrial functions were identified. In fact, it is now known that mitochondria are not only involved in cell calcium homeostasis, intermediate metabolism and free radical generation but are also a crucial crossroad for several cell death pathways. The notion that several clinically used drugs and other xenobiotics induce organ degeneration through damaging mitochondrial bioenergetics led to the use of the organelle as an effective and reliable bio-sensor to predict drug safety. Classic methods used to test the toxicity of a wide range of compounds on isolated mitochondrial fractions were later replaced by novel high-throughput methods to investigate the safety of a very large number of new molecules. Without surprise, the assessment of “mitochondrial safety” for new discovered molecules is of clear interest for pharmaceutical companies which can now select compounds lacking mitochondrial toxicity to undergo further trials, thus avoiding the possibility of later human toxicity due to mitochondrial liabilities.
Export Options
About this article
Cite this article as:
Pereira V. Claudia, Moreira C. Ana, Pereira P. Susana, Machado G. Nuno, Carvalho S. Filipa, Sardao A. Vilma and Oliveira J. Paulo, Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?, Current Drug Safety 2009; 4 (1) . https://dx.doi.org/10.2174/157488609787354440
DOI https://dx.doi.org/10.2174/157488609787354440 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design Possible Involvement of TRP Channels in Cardiac Hypertrophy and Arrhythmia
Current Topics in Medicinal Chemistry Fondaparinux: Pharmacology and Clinical Experience in Cardiovascular Medicine
Mini-Reviews in Medicinal Chemistry Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Vascular Risk Factors and Neurodegeneration in Ageing Related Dementias: Alzheimer’s Disease and Vascular Dementia
Current Alzheimer Research Systematic Review of the Role of Microparticles in Systemic Sclerosis
Current Rheumatology Reviews Substance-Related Disorders and Somatic Symptoms: How Should Clinicians Understand the Associations?
Current Drug Abuse Reviews Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design Editorial [Hot topic: Polyunsaturated Fatty Acids and Human Health: A Critical Appraisal of the Evidence (Executive Editor: Antonio Cherubini)]
Current Pharmaceutical Design Cellular Repressor of E1A-stimulated Genes, A New Potential Therapeutic Target for Atherosclerosis
Current Drug Targets The Failure of Immunomodulation Therapy in Heart Failure: Does the Statins “Paradigm” Prove the Rule?
Current Vascular Pharmacology Identifying Risk Factors for Clinically Significant Diabetic Macula Edema in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews Failing a First Anti-TNF in RA: Does it Imply a Change in Target?
Current Rheumatology Reviews Patent Selections
Recent Patents on Biomarkers Is Targeting microRNAs the Philosopher’s Stone for Vascular Disease?
Current Vascular Pharmacology Inspired Nitric Oxide and Modulation of Oxidative Stress During Cardiac Surgery
Current Drug Safety The Role of Mitochondrial Dysfunction in Heart Failure and Potential Therapeutic Targets
Current Pharmaceutical Design Omega-3 Fatty Acids and their Role in Central Nervous System - A Review
Current Medicinal Chemistry Antioxidant Evaluation of Some Semicarbazide, 1,2,4-Triazolone and Pyrazolone Derivatives
Letters in Drug Design & Discovery Histone Deacetylase Inhibition Attenuates Cardiomyocyte Hypoxia-Reoxygenation Injury
Current Molecular Medicine